Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is Bronte Capital Management Pty Ltd.’s 3rd Largest Position

Bronte Capital Management Pty Ltd. lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.5% in the 4th quarter, Holdings Channel.com reports. The firm owned 152,783 shares of the biopharmaceutical company’s stock after acquiring an additional 15,741 shares during the quarter. Regeneron Pharmaceuticals makes up about 15.8% of Bronte Capital Management Pty Ltd.’s holdings, making the stock its 3rd largest holding. Bronte Capital Management Pty Ltd.’s holdings in Regeneron Pharmaceuticals were worth $108,832,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the business. CWA Asset Management Group LLC purchased a new stake in Regeneron Pharmaceuticals during the third quarter valued at approximately $298,000. Sigma Planning Corp lifted its position in Regeneron Pharmaceuticals by 4.1% during the third quarter. Sigma Planning Corp now owns 409 shares of the biopharmaceutical company’s stock valued at $430,000 after acquiring an additional 16 shares during the last quarter. Baker Avenue Asset Management LP purchased a new stake in Regeneron Pharmaceuticals during the third quarter valued at approximately $707,000. Ashton Thomas Securities LLC lifted its position in Regeneron Pharmaceuticals by 10.5% during the third quarter. Ashton Thomas Securities LLC now owns 790 shares of the biopharmaceutical company’s stock valued at $830,000 after acquiring an additional 75 shares during the last quarter. Finally, Nations Financial Group Inc. IA ADV lifted its position in Regeneron Pharmaceuticals by 3.5% during the third quarter. Nations Financial Group Inc. IA ADV now owns 1,082 shares of the biopharmaceutical company’s stock valued at $1,137,000 after acquiring an additional 37 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $718.16 on Wednesday. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The company has a market cap of $78.51 billion, a price-to-earnings ratio of 18.76, a PEG ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20. The firm’s fifty day simple moving average is $697.08 and its two-hundred day simple moving average is $842.19.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company’s revenue was up 10.3% compared to the same quarter last year. During the same period last year, the firm posted $11.86 earnings per share. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.49%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Analysts Set New Price Targets

REGN has been the subject of a number of analyst reports. TD Cowen decreased their target price on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research report on Tuesday, February 4th. Truist Financial decreased their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. Wolfe Research assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price target on the stock. Finally, Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price target for the company from $762.00 to $834.00 in a research note on Wednesday, February 5th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.